MILAN (Reuters) -The head of the EU drug regulator's COVID-19 task force said on Sunday that AstraZeneca's coronavirus vaccine had a favourable risk-benefit profile for all age groups and particularly ...
After an all-day meeting that ran beyond its scheduled end, the safety committee of the European Medicines Agency (EMA) concluded Thursday that the benefits of receiving the AstraZeneca COVID-19 ...
LONDON – The EMA has concluded that the rare cases of serious blood clots with low platelet counts seen after administration of Astrazeneca plc’s COVID-19 vaccine are caused by the vaccine, but said ...
The European Medicines Agency (EMA) on Friday recommended a conditional marketing authorization for AstraZeneca's vaccine against COVID-19, developed in conjunction with the University of Oxford. Said ...
EMA has found AstraZeneca Covid vaccine is ‘safe and effective’ after investigation into blood clots
The European Medicines Agency has found the AstraZeneca Covid-19 vaccine is “safe” for use following an investigation into cases of blood clots among people who received the jab. It paves the way for ...
A safety panel of the European drug regulator on Friday recommended adding a rare spinal inflammation called transverse myelitis as a side effect of AstraZeneca's COVID-19 vaccine. Adds details on EMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results